B of A Securities Downgrades Conmed to Underperform, Maintains Price Target to $40

Benzinga Newsdesk www.benzinga.com Negative 79.1%

Neg 79.1% Neu 0% Pos 0%

B of A Securities analyst Travis Steed downgrades Conmed (NYSE:CNMD) from Neutral to Underperform and maintains the price target from $40 to $40.